Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Medpace Holdings Inc (MEDP) Price & Performance

iShares MSCI Taiwan ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI Taiwan ETF trades at $106.13, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). Which is the better fit depends on your goals.

EWTMEDP
Sector
Broad Market / FactorTechnology
52-Week High
$111.53$620.59
52-Week Low
$58.05$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

EWT (iShares MSCI Taiwan ETF) trades at $106.34, up 4.07% with strong bullish momentum. Technical indicators show moving averages strongly bullish while oscillators are neutral. The ETF benefits from Taiwan's AI-driven semiconductor exposure, with TSMC representing 22.5% weighting. Recent news highlights Taiwan's strong 2026 performance driven by AI chip demand, though some rotation from Asian AI winners has occurred.

Outlook remains positive given Taiwan's critical semiconductor role and AI infrastructure demand. Key risks include geopolitical tensions with China, foreign capital outflows, and semiconductor cycle volatility. The ETF's heavy tech concentration provides growth potential but increases sector-specific risk exposure.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP